>

Nuntius Therapeutics and Taiho Pharmaceutical Announce Collaboration

Expanding Presence in Specialty Pharmaceuticals

Nuntius, a biotechnology company based in London, has teamed up with Japan-based Taiho Pharmaceutical in a clinical trial agreement. With a focus on small molecule pharmaceuticals and innovative drug discovery technologies, Taiho seeks to establish itself as a trusted global presence in the specialty pharmaceutical industry.

Partnership Details

The collaboration leverages the companies' respective strengths in small molecule development and industry expertise. Nuntius brings its novel therapeutic assets to the table, while Taiho contributes its drug discovery platform technologies. By combining their resources, the partners aim to accelerate the development of cutting-edge treatments.

Shared Commitment to Innovation

Both Nuntius and Taiho share a passion for nurturing and preserving the precious moments of everyday life. This commitment to innovation and patient care drives their collaboration towards the development of new therapies that address unmet medical needs.

Collaboration Benefits

– Expansion of Taiho's global reach in specialty pharmaceuticals – Access to Nuntius' novel therapeutic assets – Leveraging Taiho's drug discovery platform technologies – Acceleration of innovative drug development – Improved patient care through access to novel treatments

About Nuntius Therapeutics

Nuntius is a London-based biotechnology company focused on developing transformative treatments for serious diseases. Their mission is to bring innovative therapies to patients through cutting-edge research and a patient-centric approach.

About Taiho Pharmaceutical

Taiho Pharmaceutical is a leading Japanese pharmaceutical company committed to discovering and developing innovative therapies. With a global presence, Taiho aims to become a trusted partner in specialty pharmaceuticals worldwide.